Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial

BACKGROUND: The recommended treatment for patients with non-metastatic muscle-invasive bladder cancer (MIBC) is neoadjuvant chemotherapy (NAC) and radical cystectomy (RC). Following NAC, 20–40% of patients experience a complete pathological response (pCR) in the RC specimen and these patients have e...

Descripción completa

Detalles Bibliográficos
Autores principales: Hinsenveld, F. J., Noordman, B. J., Boormans, J. L., Voortman, J., van Leenders, G. J. L. H., van der Pas, S. L., van Beek, S. C., Oprea-Lager, D. E., Vis, A. N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556888/
https://www.ncbi.nlm.nih.gov/pubmed/34715822
http://dx.doi.org/10.1186/s12885-021-08840-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556888/
https://www.ncbi.nlm.nih.gov/pubmed/34715822
http://dx.doi.org/10.1186/s12885-021-08840-2

Ejemplares similares